8-K: Senseonics Reports Strong Q2 Growth, Reduced Net Loss

Senseonics Holdings, Inc. announced robust second quarter 2025 financial results, driven by significant U.S. patient growth and strategic advancements.

Summary

• Total revenue for Q2 2025 reached $6.6 million, marking a 37% increase compared to $4.9 million in Q2 2024.
• U.S. revenue grew to $4.9 million in Q2 2025 from $3.0 million in Q2 2024, fueled by a 79% year-over-year increase in U.S. new patient starts.
• Gross profit significantly improved to $3.1 million in Q2 2025, up from $0.3 million in Q2 2024, primarily due to increased margins on the 365-day product and a one-time value-added tax recovery.
• Net loss decreased by $5.8 million, from $20.3 million in Q2 2024 to $14.5 million in Q2 2025, resulting in a net loss per share of $0.02.
• Research and development expenses decreased by $3.1 million year-over-year to $7.7 million, attributed to the completion of 365-day product trials.
• The company successfully raised $77.8 million in total gross proceeds, including a $57.5 million public offering and a $20.3 million private placement from Abbott.
• Full-year 2025 global net revenue is projected to be approximately $34-38 million, with an expected doubling of the global patient base.
• Full-year 2025 gross margins are anticipated to be between 32.5% and 37.5%.

Sentiment

Score: 8

Explanation: The filing presents strong positive momentum with significant revenue growth, substantial reduction in net loss, improved gross margins, and key strategic advancements like CMS reimbursement and AID system integration. The successful capital raise further strengthens the company's position for future growth, indicating a very favorable outlook despite continued net losses.

Positives

• Generated Q2 2025 revenue of $6.6 million, a 37% year-over-year increase.
• Achieved a 79% increase in U.S. new patient starts over the prior year.
• Gross profit significantly increased to $3.1 million in Q2 2025 from $0.3 million in Q2 2024.
• Net loss reduced by $5.8 million to $14.5 million in Q2 2025.
• Research and development expenses decreased by $3.1 million due to trial completion.
• Expanded direct-to-consumer (DTC) advertising campaign, leading to a 50% increase in leads.
• Completed the transition of providers to Eon Care, now with 38 providers supporting patient access.
• CMS updated the Medicare Physician Fee Schedule to provide reimbursement for a full year of Eversense 365 usage as a medical benefit.
• Entered a commercial development agreement with Sequel Med Techs to integrate their twiist automated insulin delivery (AID) system with Eversense 365.
• Successfully raised $77.8 million in gross proceeds to fund the Eversense 365 launch and pipeline development.

Negatives

• Revenue outside the U.S. decreased to $1.7 million in Q2 2025 from $1.9 million in the prior year period.
• Selling, general and administrative expenses increased by $0.7 million year-over-year to $9.7 million, driven by higher sales commissions and personnel costs.
• The company continues to operate at a net loss of $14.5 million for the quarter.

Risks

• Uncertainties inherent in the reliance on and execution of Ascensia Diabetes Care, the commercialization partner for Eversense.
• Uncertainties regarding any additional commercial support required for successful commercialization of Eversense and other commercial initiatives.
• Uncertainties in insurer, regulatory, and administrative processes and decisions.
• Uncertainties inherent in the development, registration, and roll-out of new technology and solutions.
• Uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties.
• Uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of Eversense product and company activities.
• Uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs.

Future Outlook

Senseonics continues to expect full-year 2025 global net revenue to be approximately $34-38 million, anticipating a doubling of its global patient base during 2025. Revenue generation is projected to be weighted towards the second half of the year, particularly the fourth quarter, due to Eversense 365 reorder dynamics. Gross margins are expected to increase throughout 2025, reaching between 32.5% and 37.5% for the full year, with cash used in operations estimated at approximately $60 million.

Management Comments

• "We continued to drive a strong U.S. Eversense 365 launch focused on new patients, initiating enhanced DTC advertising in June to broaden actionable leads and enable acceleration in patients and revenue growth in the second half of the year."
• "We advanced several other important strategic initiatives which drive uptake and advance our technology to position us for increased shareholder value while progressing the development of Gemini and Freedom."

Industry Context

The medical technology sector, particularly continuous glucose monitoring (CGM), is experiencing significant growth driven by increasing diabetes prevalence and demand for advanced management solutions. Senseonics' focus on long-term implantable CGM systems positions it uniquely within this market. The reported 79% increase in U.S. new patient starts and the CMS reimbursement update for Eversense 365 indicate strong market adoption and favorable regulatory support, aligning with the broader trend of expanding access to innovative diabetes care technologies. The integration agreement with Sequel Med Techs for an automated insulin delivery (AID) system reflects the industry's move towards integrated, holistic diabetes management solutions, enhancing patient convenience and outcomes.

Comparison to Industry Standards

• The 37% year-over-year revenue growth and 79% U.S. new patient growth for Senseonics' Eversense 365 system are strong indicators of market penetration and adoption, particularly when compared to the overall CGM market, which is projected to grow at a CAGR of 10-15% in the coming years. This suggests Senseonics is capturing a significant share of new users.
• The improvement in gross profit from $0.3 million to $3.1 million, driven by increased margins on the 365-day product, demonstrates improved operational efficiency and scalability, a critical factor for medical device companies as they ramp up production and sales.
• The CMS update providing reimbursement for a full year of Eversense 365 usage as a medical benefit is a significant competitive advantage, as favorable reimbursement policies are crucial for widespread adoption of high-cost medical devices, potentially putting Senseonics on par with or ahead of competitors in terms of patient access through Medicare.
• The collaboration with Sequel Med Techs to integrate Eversense 365 with the twiist AID system positions Senseonics to compete with integrated solutions offered by larger players like Dexcom (G6/G7 with insulin pumps) and Abbott (Freestyle Libre with various insulin delivery partners), indicating a strategic move towards comprehensive diabetes management platforms.

Related Party Transactions

• Revenue, net related parties: $3.426 million for Q2 2025 and $7.873 million for the six months ended June 30, 2025.
• Accounts receivable, net related parties: $2.304 million as of June 30, 2025.
• Accrued expenses and other current liabilities, related parties: $2.624 million as of June 30, 2025.
• Abbott participated in a $20.3 million private placement as part of the capital raise.
• Ascensia Diabetes Care is the exclusive global distribution partner for Eversense.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, and strategic advancements, though dilution from the public offering is noted. The capital raise provides funding for future growth.
• Patients: Enhanced access to Eversense 365 through increased U.S. new patient starts, expanded DTC advertising, CMS reimbursement for full-year usage, and the upcoming integration with an automated insulin delivery system.
• Healthcare Providers: Improved support and access through the transition to Eon Care with 38 providers, facilitating patient insertions.
• Employees: Increased sales commissions and personnel costs indicate growth in sales and support teams.
• Partners (Ascensia, Abbott, Sequel Med Techs): Strengthened collaborations and new development agreements indicate continued strategic alignment and potential for mutual growth.

Next Steps

• Continue the roll-out of Eversense 365 to U.S. patients.
• Generate approximately two-thirds of full-year 2025 revenue in the second half of the year, weighted towards the fourth quarter due to reorder dynamics.
• Execute on spending for the DTC marketing campaign to generate additional leads.
• Implement other sales and marketing initiatives.
• Utilize and assess the impact of patient assistance programs for Eversense 365.
• Continue progress with the transition of reimbursement from Eversense E3 to Eversense 365.
• Launch the integrated Sequel Med Techs twiist AID system with Eversense 365, expected in Q4.
• Progress the development of Gemini and Freedom pipeline products.
• Host a conference call on August 6, 2025, to discuss financial results and business developments.

Key Dates

Recommendation

The filing indicates strong operational improvements and strategic advancements for Senseonics. The significant year-over-year revenue growth (37%), substantial increase in U.S. new patient starts (79%), and a notable reduction in net loss demonstrate positive momentum. The improved gross profit margins and the successful $77.8 million capital raise provide a stronger financial foundation for future growth. Key strategic initiatives, such as CMS reimbursement for full-year Eversense 365 usage and the integration agreement with Sequel Med Techs for AID, are expected to drive further adoption and market expansion. While the company is still operating at a loss, the positive trends in key metrics and the clear path to increased market penetration suggest a favorable outlook for long-term investors.

Keywords

Continuous Glucose Monitoring, CGM, Diabetes Management, Eversense, Medical Technology, Implantable Devices, Financial Results, Patient Growth, Healthcare Reimbursement, Insulin Delivery Systems